Cancer
01 Jan 2013
R-GIFOX for Relapsed and Refractory Aggressive Non-Hodgkin’s Lymphoma
Aim: To evaluate the clinical activity, toxicity and mobilizing capacity of a new short-course (bi-weekly), dose intensive, cytoreductive/mobilizing salvage regimen (R-GIFOX) combining the cross-synergistic agents Gemcitabine (G), Ifosfamide (Ifo), Oxaliplatin (Ox) and Rituximab (R) in patients with relapsed and refractory CD20+ NHL. Conclusions: R-GIFOX was feasible, tolerable, effective…
Blood
01 Jan 2013
Comparison between Cy then G-CSF and IVE Plus G-CSF in Haematological Malignancies
Aim: To retrospectively compare the PBPC yields of harvests after IVE with those of standard Cy/G-CSF priming. Conclusions: Priming with IVE yields higher PBPC numbers than cyclophosphamide, patients requiring fewer pheresis, therefore reducing the cost. Official Title A Retrospective Comparison between Cyclophosphamide (Cy) Followed by G-CSF, and…
Cancer
01 Jan 2013
Phase I/II Study of Concurrent Chemoradiotherapy for Newly-Diagnosed, Localized Nasal NK/T-Cell Lymphoma: Results of a Phase I Portion of JCOG0211-DI
Aim: To explore a more effective treatment for newly-diagnosed localized nasal NK/T-cell lymphoma, we conducted a multicenter phase I/II study of concurrent chemoradiotherapy. Conclusions: Researchers concluded results suggest that concurrent chemoradiotherapy using MDR- non-related agents and ETP is a promising treatment strategy for localized nasal NK/T-cell…
Cancer
01 Jan 2013
HD Chemoradiotherapy and ASCT Can Overcome the Prognostic Importance of Bcl-2, Bim, and p53 in Relapsed/Refractory Hodgkin’s Lymphoma
Aim: Prior studies showed that overexpression of bcl-2 and p53 have negative impact on outcome with primary therapy. The study sought to determine if the comprehensive second-line program could overcome these poor prognostic features. Conclusions: Researchers concluded that despite the evidence that p53 and bcl-2 overexpression may predict…
Cancer
01 Jan 2013
The Utility of Consolidative Upfront High Dose Chemoradiotherapy and ASCT in Patients with Mantle Cell Lymphoma (MCL)
Aim: To improve progression-free survival (PFS) in MCL using a strategy of incorporating approaches of intensifying induction & intensifying consolidation with high dose chemo radiotherapy (HDT by administering an anthracycline-containing regimen in a dose dense fashion CHOP- or R-CHOP-14) followed by consolidation with ICE HDT/ASCT. Conclusions: Researchers…
Cancer
01 Jan 2013
An Outpatient Salvage Approach for Advanced Lymphoma Incorporating Stratification and Dose-Escalation
Aim: To assess efficacy and toxicity of 2 and 3 drug salvage regimens. Conclusions: Researchers concluded that both VGF and F-GIV can be safely administered on an outpatient basis and show activity against advanced lymphoma Official Title Conditions Study Type Phase II Study Design Patients were stratified into:…
Cancer
01 Jan 2013
RADAR Trial – Randomised Androgen Deprivation and Radiotherapy
Purpose The principal objectives of the RADAR trial is to address the hypotheses; 1) that 18 months androgen deprivation in conjunction with radiotherapy is superior to 6 months androgen deprivation prior to and during radiotherapy; 2) that 18 months Bisphosphonate therapy will prevent bone loss caused by androgen deprivation…
Cancer
01 Jan 2013
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
Rationale: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Purpose: This randomized phase III trial is studying how well androgen deprivation therapy works in treating patients with prostate cancer. Official Title Phase III Randomized Study of Delayed…
Cancer
01 Jan 2013
Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which chemotherapy regimen is more effective, or whether chemotherapy is more effective than observation, in treating pancreatic cancer after surgery. PURPOSE: Phase III trial…
